TechSurge: Deep Tech Podcast · Celesta Capital | Deep Tech Venture Capital Firm

Why AI Isn't Ready to Make Medicines

March 13, 2025·42 min·3 clips
AI expands the search radius for drug discovery, but the sequence space is like a solar system of possibilities.
Mike Nohaly, a biotech leader, argues that AI is overhyped for creating new medicines, citing data limitations and a lack of de novo drugs. He explains the need for better treatments, outlines the history of drug development waves, and introduces Prellis Biologics' human organoid technology as a promising alternative for antibody discovery.

As heard by us

A sober check on AI drug discovery that favors substance over hype.

The episode makes a firm case that AI drug discovery is still a long way from living up to the hype. It is strongest when it sticks to concrete points: antibodies, the gap between a sequence that is merely new and one that actually reaches a new target, and the bigger problem of…

Read the full review in PlayNext →

Why you'd press play

Hear why AI drug discovery may still be decades away from prime time, and why the bottleneck is data.

Read the full recommendation in PlayNext →
Listen to the show on